Filgrastim, used to prevent febrile neutropenia (FN) in patients undergoing chemotherapy, is the first drug in the United States to have a biosimilar approved. While the biosimilar filgrastim was approved in 2015, few studies have compared the real-world incidence of FN, healthcare resource utilization, and costs among US patients using the reference product (Neupogen) and those using the approved biosimilar (Zarxio).
Filgrastim, used to prevent febrile neutropenia (FN) in patients undergoing chemotherapy, is the first drug in the United States to have a biosimilar approved. Since its 2015 approval, few studies have compared the real-world incidence of FN, healthcare resource utilization, and costs among US patients using the reference product (Neupogen) and among those using the approved biosimilar (Zarxio).
A new study, published in the Journal of Managed Care & Specialty Pharmacy, reports on a retrospective claims analysis of patients with nonmyeloid cancer who were enrolled in commercial or Medicare Advantage plans between 2015 and 2016, and who received either the reference or the biosimilar filgrastim during their first observed chemotherapy cycle.
The research team, led by Lee Schwartzberg, MD, used the Optum Research Database to identify patients 18 years or older who had at least 1 claim for filgrastim following the first cycle of chemotherapy. A total of 3542 patients met inclusion criteria, of whom 172 received the biosimilar and 3370 received the reference filgrastim. Weighted cohorts were created using inverse probability of treatment weighting to arrive at a 162-patient biosimilar cohort and a 3297-patient reference cohort.
The researchers found that the incidence of FN between the weighted treatment cohorts was statistically equivalent (90% CI of the difference of percentages was within ±6%), as well as the following:
With respect to costs, the researchers found the following:
Considering the high cost of FN and the potential for prophylaxis with filgrastim to save on costs, say the authors, underutilization of the reference and biosimilar filgrastim has serious consequences in terms of healthcare costs.
“Given that [the biosimilar] is less costly than [the reference]…increasing use of the biosimilar has the potential to promote guideline compliance by improving drug access,” write the authors. “This scenario has already been borne out in Europe, where burgeoning acceptance of biosimilar filgrastim since its 2008 approval has led to more widespread use of prophylaxis, suggesting that health care providers are more able and/or willing to follow clinical guidelines now that the biosimilar is available.”
Reference
Schartzberg LS, Lal LS, Balu S, et al. Clinical outcomes of treatment with filgrastim versus a filgrastim biosimilar and febrile neutropenia—associated costs among patients with nonmyeloid cancer undergoing chemotherapy [published online April 24, 2018]. J Manag Care Spec Pharm. doi: 10.18553/jmcp.2018.17447.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Patients With IBD Maintain Therapy 2 Years Post Switching to Infliximab Biosimilar
March 23rd 2025People with inflammatory bowel disease (IBD) who switched to the infliximab biosimilar CT-P13 had higher treatment persistence (84% and 91%) than those new to infliximab (66% and 53%), with no new safety concerns.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.